CCC is pleased to announce that it was awarded a contract by the United States Department of War (U.S. DoD) to provide the most advanced Photo-Cat Oxidation system available to the U.S. Navy.
Cluster 4/5 was treated with the dual ICI regimen of ipilimumab plus nivolumab. This arm remains open to accrual. Clusters 3, 6, and 7 were excluded from the study. Additional secondary endpoints are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback